XTL Biopharm SP (XTLB) Swings to Q3 Loss
Tweet
Share
E-mailGet Alerts XTLB Hot Sheet
Join SI Premium – FREE
XTL Biopharm SP (Nasdaq: XTLB) reported Q3 EPS of $-0.00, versus $0.00 reported last year. Revenue was $287 thousand, versus $473 thousand posted in Q313.
For earnings history and earnings-related data on XTL Biopharm SP (XTLB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rivian reports record Q3 deliveries, beats estimates, shares rise
- DBS cuts Sea target as Shopee spending weighs on profit growth
- Cuprina to buy seven-clinic Singapore healthcare group for S$4M
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
